| Literature DB >> 32278435 |
Laureen Coic1, Pierre-Yves Sacré2, Amandine Dispas3, Elodie Dumont2, Julie Horne2, Charlotte De Bleye2, Marianne Fillet4, Philippe Hubert2, Eric Ziemons2.
Abstract
This paper addresses the issue of pharmaceutical solid dosage form quantitation using handheld Raman spectrophotometers. The two spectrophotometers used are designed with different technologies: one allows getting a more representative sampling with the Orbital Raster Scanning technology and the other one allows setting acquisition parameters. The goal was to evaluate which technology could provide the best analytical results. Several parameters were optimized to get the lowest prediction error in the end. The main objective of this study was to evaluate if this kind of instrument would be able to identify substandard medicines. For that purpose, two case-study were explored. At first, a full ICH Q2 (R1) compliant validation was performed for moderate Raman scatterer active pharmaceutical ingredient (API) in a specific formulation. It was successfully validated in the ±15% relative total error acceptance limits, with a RMSEP of 0.85% (w/w). Subsequently, it was interesting to evaluate the influence of excipients when the API is a high Raman scatterer. For that purpose, a multi-formulation model was developed and successfully validated with a RMSEP of 2.98% (w/w) in the best case. These two studies showed that thanks to the optimization of acquisition parameters, Raman handheld spectrophotometers methods were validated for two different case-study and could be applied to identify substandard medicines.Entities:
Keywords: Accuracy profile method validation; Pharmaceutical tablets; Quantitative performances; Raman handheld spectrophotometer; Uniformity of dosage unit
Year: 2020 PMID: 32278435 DOI: 10.1016/j.talanta.2020.120888
Source DB: PubMed Journal: Talanta ISSN: 0039-9140 Impact factor: 6.057